Pharmacological Interventions to Decompression Sickness in Rats: Comparison of Five Agents

ELIZABETH A. MONTCALM-SMITH, ANDREAS FAHLMAN, AND SUSAN R. KAYAR


Introduction: This research investigated whether decompression sickness (DCS) risk or severity could be reduced using drug interventions that are easier to implement and equal to or more efficacious than recompression therapy. Methods: Using a rat model of DCS, anti-inflammatory or anticoagulant drugs, including lidocaine, aspirin (ASA), methylprednisolone (MP), alpha-phenyl-N-butyl nitroprone (PBN), and transsodium crocetinate (TSC) were tested to determine their effect on incidence of DCS, death, and time of symptom onset. Each treatment group consisted of ~40 animals that received the drug and ~40 controls. Animals were exposed to one of five compression and decompression profiles with pressure ranging from 6.3 ATA (175 fsw) to 8.0 ATA (231 fsw); bottom time was either 60 or 90 min; and decompression rate was either 1.8 or 15 ATA min⁻¹. Following decompression, the rats were observed for 30 min while walking on a wheel. DCS was defined as an ambulatory deficit or abnormal breathing. Results: None of the drugs reached statistical significance for all DCS manifestations. Lidocaine post-dive and MP were the only treatments with marginally (P < 0.15) significant differences in DCS outcomes compared to controls. Lidocaine post-dive significantly decreased the incidence of neurological DCS from 73-51%. MP significantly extended the time of onset of death from DCS from 5.4 min to 7.1 min. Discussion: Of the treatments investigated, lidocaine given post-dive has the best chance of success in adjuvant therapy of DCS. Future studies might investigate adjuvant drugs given in combination or during recompression. Keywords: DCS, adjunctive therapy, lidocaine, aspirin, methylprednisolone, transsodium crocetinate, alpha-phenyl-N-butyl nitroprone.

Decompression sickness (DCS) is a systemic pathophysiological process that may occur with a decrease in atmospheric pressure. The pressure reduction results in bubbles of inert gas, usually nitrogen, within body tissues. Originally, it was believed that the bubbles caused mechanical damage to cells by displacing and deforming adjacent structures, tearing vessels, or obstructing vessels, leading to ischemia (22). However, the full spectrum of pathology found in DCS cannot be explained solely by the hypothesis of bubble-induced mechanical obstruction of the vasculature (16). It is now believed that the body's host defenses respond to bubbles as foreign bodies, leading to the activation of enzymes, complement and clotting factors, and the release of vasoactive substances (48). The activation of the body's defense system initiates a vicious cycle that leads to multiple organ failure unless the DCS is adequately treated. In fact, the longer the treatment is delayed, the greater the chance of treatment failure, residual symptoms, permanent sequelae, or death (35).

Many parallels may be drawn between Type I DCS and inflammation. It has been suggested that the joint pain, itching, and malaise associated with Type I DCS is caused by bubbles acting as immunogens, stimulating the release of histamine, serotonin, or prostaglandins. These bioactive molecules are associated with an increase in vascular permeability, leading to tissue edema and loss of intravascular volume. Edema in any tissue may sufficiently increase tissue pressure, blocking capillary perfusion, leading to a "no-reflow" phenomenon that promotes ischemic damage and inert gas bubble growth (35). Edema in neurological tissue could damage neurological membranes, perhaps the source of neurodeficits in Type II DCS (33). Reduced intravascular volume itself is a problem that induces a state of shock (16).

If the immune system response to bubbles activates leukocytes, these cells may migrate out of the vascular space. While free in the extracellular tissues, leukocytes may release proteolytic enzymes that damage tissues (33). Additionally, the transendothelial migration of leukocytes tends to damage the vessel walls, activating platelets and other blood cells or proteins (38). Plasma proteins such as fibrinogen may cause blood clots and abnormal hemostasis; blood cells may adhere to the damaged wall sites, releasing more histamine, perpetuating the chain of inflammatory events. There is a wide range of possible drug therapies that could reduce or eliminate these problems, depending on the immunological pathway activated.

The purpose of this research was to determine if DCS risk or severity could be reduced using available drug interventions. Drug therapies against DCS have been considered by others, with varying levels of success.
We examined lidocaine in a rat model using two different therapeutic strategies. In one series we treated with lidocaine immediately before a dive using a rapid decompression rate that favors neurological symptoms of DCS. In the other series, lidocaine therapy was delivered in several doses immediately after decompression, using a slower ascent rate associated with pulmonary DCS symptoms in addition to neurological symptoms. We used low therapeutic dose levels as this tends to preserve conduction in isolated nerves and inhibits cation leakage (13).

**Aspirin (ASA)**

Nonsteroidal anti-inflammatory agents have been proposed as prophylactics against DCS because they inhibit platelet activation and aggregation. They also suppress the concomitant cascade of inflammatory events and decrease free radicals and superoxide (5). One of the most widely used drugs in the world, ASA exerts its efficacy via acetylation of the cyclooxygenase enzyme (COX). The acetylation occurs rapidly and leads to irreversible inhibition of the COX enzyme (47). Low doses of ASA (30–50 mg·d⁻¹) inhibit the activity of cyclooxygenase type 1 (COX-1), decreasing the production of thromboxane A₂ and platelet aggregation (39). Higher doses over longer periods inhibit COX-2 and nonspecifically acetylate a variety of proteins and nucleic acids. This is the basis for the anti-inflammatory effects (47). ASA is rapidly absorbed, yielding a peak serum level within 1–2 h.

Several laboratories have investigated the effect of ASA on DCS. Popovic and colleagues reported a reduction in DCS incidence from 40% in untreated control rats to 22% in rats given ASA (55 mg·kg⁻¹) in their drinking water for 30 d prior to a dive (41). Philp et al. reported modest but not statistically significant success with ASA, as measured by the reduction in circulating platelet count, when given orally in men (325 mg three times per day) for 2 d prior to diving (40). In contrast, Bennett and Brock reported no benefits from ASA (100 mg·kg⁻¹) administered orally to rats 1 h predive (3). We, therefore, chose to test if chronic oral administration of a 100 mg·kg⁻¹ dose would affect DCS outcome in a rat model using two protocols: 1) a rapid decompression rate favoring neurological symptoms of DCS (ASA₁rapid), and 2) a slower decompression rate associated with pulmonary DCS symptoms in addition to the neurological symptoms (ASA₁slow).

**Methylprednisolone (MP)**

An anti-inflammatory steroid, MP has been suggested as a DCS therapy because it may reduce cerebral edema caused by gas emboli (5). MP may also improve blood flow to brain regions injured by gas emboli by reducing the adherence of leukocytes to damaged vascular endothelium (17). In swine subjected to a 24-h saturation dive, MP administered 24 h prior to decompression did not protect against DCS; in fact, it increased the death rate of animals with DCS (15). However, after 24 h, the MP was probably no longer at its peak activity. Consideration of corticosteroids as emergency therapy for DCS persists (10) based on their anti-inflammatory action (5,42) and because some trials showed long-term benefits from MP in patients suffering from spinal cord trauma (6). Treatment of DCS with another glucocorticoid, Dexamethasone, did not appear to influence the outcome of DCS (20). We used a rat model of DCS to test the predive administration of MP using our dive protocol that favors neurological symptoms of DCS.

**Alpha-Phenyl-N-Tert-Butylnitrone (PBN)**

A nitrone-based free radical trap, PBN reacts covalently with reactive O₂ species (ROS) to form stable nitrone oxides. A study examining tissue distribution, excretion, and metabolism of PBN showed that PBN is rapidly absorbed, widely distributed, and remains for a lengthy period in many tissues when injected intraperitoneally in mice (28). Nitrones are neuroprotective in rodent models of central nervous system ischemia (8) and transient compression of the spinal cord (19). Significant protection was evident with administration as late as 12 h post-ischemia. PBN also minimized ferrous ion-induced seizures and delayed time to death in mice given 20 min prior to iron injections (33). The nitrone-based free radical scavengers have demonstrated potent neuroprotection in stroke models in which oxidative stress plays a key role (25). The therapeutic mechanism...
of neuroprotection from nitrones is unknown, but current research suggests two major hypotheses: 1) mass-action free radical trapping; and 2) inhibition of enhanced signal transduction associated with neuroinflammatory processes.

Transsodium Crocetinate (TSC)

TSC is a carotenoid compound. It is a long molecule and computer models suggest that it affects the structure of water (23). For example, crocetin, a similar molecule, forms a hydration shell that has been suggested to increase O$_2$ diffusivity. Molecular dynamics simulations suggest that the mechanism is due to the interactions of the hydrophobic TSC molecules and plasma (23). If plasma is the postulated site of major diffusive resistance to O$_2$ transport between erythrocytes and tissue (26), then it might be helpful to increase diffusivity. The diffusivity of O$_2$ through plasma is lower than it is through water, perhaps due to the presence of plasma proteins (36). Although TSC has not been extensively studied, crocetin has been examined in a number of O$_2$-related experiments and was shown to increase O$_2$ diffusivity through plasma by 30% (23). Unlike fluoro-carbons or hemoglobin, crocetin does not bind O$_2$ or increase its solubility in blood plasma but increases O$_2$ consumption during hemorrhagic shock (24). TSC increased mean arterial blood pressure immediately and reduced tachycardia in a rat model of hemorrhagic shock (24). Some have suggested that when given during resuscitation from hemorrhage, crocetin restores cellular energy levels and reduces apoptosis (46). Interestingly, it has been suggested that TSC and O$_2$ therapy show similar results when used in a rat hemorrhage model (24). We tested a high and a low dose of TSC administered predive as a prophylaxis against DCS in a rat model that favors neurological symptoms of DCS. The dosages of TSC were similar to those used in hemorrhagic shock studies.

This study explored pharmacological interventions described above in rat models of DCS. Our goal was to systematically examine whether any of these drugs held promise as a means of reducing the incidence or severity of DCS.

METHODS

Animals

Male Sprague-Dawley rats (Rattus norvegicus, 240-311 g) were examined on receipt by the veterinary staff and housed in the animal care facility. They were stabilized for 7 d, and maintained under a 12-h light/dark cycle with ad libitum access to standard rat chow and water prior to the experiment. The experiments reported were conducted according to the principles set forth in the "Guide for the Care and Use of Laboratory Animals," Institute of Laboratory Animal Resources, National Research Council, National Academy Press. The Institutional Animal Care and Use Committee reviewed and approved all aspects of this protocol. The institutional animal care facility is fully AAALAC accredited.

The mean body mass (± SD) immediately before dive experiments was 271 ± 18 g for all animals, and the body mass for each treatment and control group pairs were closely matched in body mass (means within 0–9 g of each other, with SDs per group of 1–6 g).

Drug Treatments

Each treatment regimen had its own control group and animals were randomly assigned either treatment or control groups. In experiments that required venous access, animals had a small-gauge cannula placed in the tail vein. Sterile saline was used as a flush and control injectate in all control groups.

Lidocaine was delivered either immediately predive (L$_{pre}$, 1.2 mg · kg$^{-1}$) or 5 min (1.2 mg · kg$^{-1}$), 10 min (0.12 mg · kg$^{-1}$), and 15 min (0.12 mg · kg$^{-1}$) after the start of decompression (L$_{post}$). This low dose was selected to allow animals to remain able to walk, despite the anesthetic properties of lidocaine (7). ASA was dissolved in water and administered by gavage at a dose of 100 mg · kg$^{-1}$ three times daily for 2 d before dive experiments (3,40). A gavage of water of the same volume and timing as the aspirin treatments was used for the controls. MP (20 mg · kg$^{-1}$) was injected i.v. 4.5 h before the dive to allow the drug to reach its peak at the time of decompression (27,36). PBN was injected at a dose of 150 mg · kg$^{-1}$ i.p. immediately predive (11,19,25,28).

TSC solutions were distilled, de-ionized water to which 0.0001 M sodium carbonate had been added drop-wise until the pH was 8.0 and were injected i.v. TSC was administered i.v. immediately upon reaching the surface and a second dose was given 15 min later at either a high (TSC$_{high}$ 0.81 mg · kg$^{-1}$) or low dose (TSC$_{low}$ 0.27 mg · kg$^{-1}$). This dose is higher than the threshold dose of 0.1-0.2 mg · kg$^{-1}$ and lower than the maximum tested without deleterious side effects (24).

Dive Protocols

Dive protocols were derived from the work of Lillo et al., with pressure and duration selected for a high incidence of DCS in untreated rats of this body mass (29). Rats were exposed in groups of 4 per dive, approximately 40 per experimental group, for a total of 633 animals for this study. The animals were placed in a wire mesh cylindrical drum divided into separate sections along the axis of rotation, one rat per section. The drum was placed inside a hyperbaric chamber and rotated at 3.6 m · min$^{-1}$, obligating the rats to walk at a moderate pace during and after the exposure. Two general dive profiles were used with the intention of causing rats to have a high incidence of DCS, with some variation in the frequency of either pulmonary or neurological DCS symptoms (30). It has previously been shown that a compression to 150–200 fsw for 60 min with a decompression rate at 60 fsw · min$^{-1}$ results in a high incidence of pulmonary DCS in addition to neurological symptoms. A similar dive depth and duration but with a much more rapid decompression, within 30 s, is likely to induce primarily neurological DCS symptoms (29).
Compression and decompression schedules for each of the treatment groups were as follows:

The L$_{pre}$ ASA$_{rapid}$ and PBN groups were compressed to 220 fsw (7.67 ATA) for 90 min and decompressed at a rate of $-15$ ATA·min$^{-1}$ ($<30$ s). The L$_{post}$ and ASA$_{slow}$ groups were compressed to 231 fsw (8.0 ATA) for 90 min and decompressed at a rate of $-15$ ATA·min$^{-1}$ ($<30$ s). The MP group was compressed to 231 fsw (8.0 ATA) for 90 min and decompressed at a rate of $-15$ ATA·min$^{-1}$ ($<30$ s).

The animals were observed throughout the dive via ports on the chamber. Immediately post-decompression, the drum was removed from the chamber but continued to rotate for 30 min at the same speed, with a mill on the laboratory benchtop. Onset of DCS was recorded to the nearest 30 s by a dedicated observer who was not blinded to the treatment. Signs and symptoms of neurological DCS included limping, sideways gait, failure to maintain balance, falling, difficulty righting after a fall, or rolling passively; signs of pulmonary DCS were abnormal breathing. After the 30-min observation period, all surviving animals were euthanized by injection of pentobarbital.

Statistical Analysis

Mean values reported are $\pm 1$ SE. Significance was established at the $P < 0.05$ level. Group differences in mean time to DCS onset and death (Table I) were analyzed by a single factor analysis of variance (ANOVA).

The measure of effect for treatment efficacy was the difference between the control and drug incidence for DCS and mortality. StatXact with Cytel Studio (Version 6; Cytel, Cambridge, MA) was used to compute exact 95% confidence intervals (CI) on the difference between the proportions of events in the control group minus the proportion of events in the treated group. Differences in time to onset between control and treated animals were examined by constructing Kaplan-Meier curves; the log rank test was used to assess significance in survival.

**TABLE I. TIME TO ONSET OF DCS OR DEATH IN EACH PROTOCOL.**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Mean Time to DCS onset (min)</th>
<th>Mean Time to Death (min)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control</td>
<td>Treated</td>
</tr>
<tr>
<td>L$_{pre}$</td>
<td>4.3 $\pm$ 0.3</td>
<td>4.6 $\pm$ 0.4</td>
</tr>
<tr>
<td>L$_{post}$</td>
<td>8.9 $\pm$ 0.3</td>
<td>9.4 $\pm$ 0.7</td>
</tr>
<tr>
<td>ASA$_{rapid}$</td>
<td>6.0 $\pm$ 0.7</td>
<td>5.6 $\pm$ 0.8</td>
</tr>
<tr>
<td>ASA$_{slow}$</td>
<td>10.3 $\pm$ 0.7</td>
<td>9.3 $\pm$ 0.6</td>
</tr>
<tr>
<td>MP</td>
<td>4.8 $\pm$ 0.6</td>
<td>5.5 $\pm$ 0.6</td>
</tr>
<tr>
<td>PBN</td>
<td>4.1 $\pm$ 0.5</td>
<td>3.0 $\pm$ 0.3</td>
</tr>
<tr>
<td>TSC$_{low}$</td>
<td>6.6 $\pm$ 0.8</td>
<td>6.6 $\pm$ 1.1</td>
</tr>
<tr>
<td>TSC$_{high}$</td>
<td>5.0 $\pm$ 0.8</td>
<td>5.0 $\pm$ 0.7</td>
</tr>
</tbody>
</table>

* Significantly different from paired control group, $P < 0.05$.

Symbols: lidocaine pre- (L$_{pre}$) or post-dive (L$_{post}$); aspirin, slow decompression (ASA$_{slow}$); aspirin, rapid decompression (ASA$_{rapid}$); methylprednisolone (MP); alpha-phenyl-N-tert-butylnitrone (PBN); transsodium crocetinate, low dose (TSC$_{low}$); transsodium crocetinate, high dose (TSC$_{high}$).

Since the mean predive weight for control and treatment groups were similar, the crude (i.e., unadjusted) estimates of hazard ratios were calculated.

RESULTS

Figs. 1A and B summarize the drugs tested based on 95% CI on the difference between the proportion of events between the control and drug treatment groups. Differences $>0$ indicate evidence of treatment benefit. All CIs failed to exclude zero; thus none of the drugs reached statistical significance at the $P = 0.05$ level. For L$_{post}$, the estimated confidence interval on the difference in DCS proportions lay almost entirely (97.6%) to the right of zero, but there was no difference in mean

![Graph A](image1.png)

![Graph B](image2.png)

**Fig. 1.** Treatment effect on DCS A) incidence and B) death. Measure of effect $=$ $p_c$(control) minus $p_t$(treatment), where $p$ is incidence rate. Solid circles show means; bars indicate 95% confidence intervals. Treatments were: lidocaine pre- (L$_{pre}$) or post-dive (L$_{post}$); aspirin, slow decompression (ASA$_{slow}$); aspirin, rapid decompression (ASA$_{rapid}$); methylprednisolone (MP); alpha-phenyl-N-tert-butylnitrone (PBN); transsodium crocetinate, low dose (TSC$_{low}$); transsodium crocetinate, high dose (TSC$_{high}$).
DCS incidence ($\chi^2 = 3.1, P < 0.1$). Methylprednisolone was the only other treatment associated with a $P$-value $< 0.15$ ($\chi^2 = 2.2, P < 0.15$). With regard to contrasting death rates between the control and treated groups (Fig. 1B), all eight treatments produced two-sided $P$-values $> 0.20$.

Times to onset of DCS symptoms and death for all treatment groups are presented in Table I. For MP, there was a statistically longer mean time to onset of death compared to controls ($7.1 \pm 0.6$ versus $5.4 \pm 0.6$ min; $\chi^2 = 3.9, P < 0.05$). A log-rank survival analysis showed that there was a significantly ($P < 0.05$) longer time to onset of DCS in the MP group (Fig. 2). However, the survival analysis (not significantly different, $P > 0.10$) did not agree with the test of mean time to death with MP treatment. The only other drug treatment with marginally longer time to onset of DCS compared to controls was the $L_{post}$ group ($\chi^2 = 2.8, P < 0.1$).

The mechanisms of action for ASA and lidocaine suggested that these drugs might have a differential effect on physiological processes that would be evident in neurological vs. pulmonary manifestations of DCS. Consequently, two different compression and decompression schedules were used, with the expectation that the slower decompression rate would yield a greater incidence of pulmonary DCS ($L_{pre}$ and $L_{post}$). Table II presents these results by neurological (limping, limb paralysis, seizures) and pulmonary (labored breathing, coughing) symptoms. Many animals displayed both sets of symptoms; consequently their sum does not equal the total DCS for each group.

There were no significant differences between control and treated animals in the incidence of neurological versus pulmonary DCS for either decompression profile of ASA or for the $L_{pre}$ group ($P > 0.20, 1$ d.f., $\chi^2$ test; Table II). However, in the $L_{post}$ there were significantly fewer neurological manifestations of DCS compared to controls ($51\%$ versus $73\%$; $P < 0.05, 1$ d.f., $\chi^2 = 4.1$; Table II), and a trend toward fewer pulmonary symptoms ($66\%$ versus $46\% P < 0.10, 1$ d.f., $\chi^2 = 3.2$; Table II).

**DISCUSSION**

Since recognizing DCS as a possible inflammatory response, rather than a phenomenon exclusive to gas supersaturation and bubble load, researchers have pursued drug therapies targeting the inflammatory cascade (5). While recompression followed by controlled decompression is standard treatment, an effective adjunctive therapy could prevent or minimize secondary pathophysiological pathways. Our research examined several current leading candidates.

Lidocaine was chosen for its myriad effects on membranes and medication of inflammation. Our data suggest that lidocaine has no effect on DCS incidence when given predive (Table II; Fig. 1). However, our data also indicated a trend that survival time before DCS was longer in the $L_{post}$ group, suggesting some temporary individual benefit, but no general benefit in this animal model. $L_{post}$ rats showed a trend toward lower DCS incidence (Fig. 1), and a statistically significant reduction of neurological DCS (Table II). We opted to use a conventional low dose of lidocaine (33) that permitted animals to walk, versus higher anesthetic doses that might have left animals unable to stand. Low dose injection of lidocaine has had neuroprotective effects while higher doses have had inconsistent effects (7,13,31,33). Elevated lidocaine doses decrease cerebral blood flow and lead to metabolic stress (33), and would be impractical as a predive prophylactic if it left divers unable to work. It is uncertain if higher doses than we tested post-dive would lead to a statistically significant reduction in DCS. It may be useful to test higher doses of $L_{post}$ to produce plasma levels of 1-2 $\mu$g·ml$^{-1}$ (44). It may also be worth examining lidocaine in a larger animal model with physiological monitoring to determine the modes of action and the possibility of augmenting beneficial effects.

Our results corroborate those of Bennett and Brock (3) that ASA did not alter the incidence of DCS or death, but differ from Popovic et al. (41), who found a significant reduction in DCS following ASA administration. The dosage we tested was nearly double that of Popovic et al., but we administered ASA for 3 d predive, versus 30 d predive in the Popovic et al. study. Our dives saturated the rats with nitrogen (29), whereas the Popovic dives...
were of 30 min duration, which is subsaturated. We do not know how these differences in protocol may have contributed to the disparate results.

The ineffectiveness of ASA against DCS may be due to its inability to inhibit leukocyte activation and adherence. There has been some speculation that inhibition of platelet activation by ASA might exacerbate neurological DCS if there is bleeding in neurological tissues caused by bubble damage. Due to its ubiquitous use, it is important to note that this study finds that ASA administered prior to hyperbaric exposure does not increase the incidence of either neurological or cardiopulmonary DCS.

Our results show that MP might offer benefit as an adjuvant treatment for DCS in a rat model. MP caused a statistically significant delay in the onset of DCS (Fig. 2), but DCS incidence was the same in treated and control animals. Although high-dose MP is commonly administered after spinal cord injury, this is not the case with DCS. While MP has never been tested in humans for DCS, animal studies show that it did not protect against severe DCS; in fact, treated animals with DCS had higher mortality (14). In addition, there are potentially serious adverse reactions to the use of parenteral corticosteroids, such as gastrointestinal bleeding and pancreatitis. Mega-dose MP has been associated with anaphylaxis, hyperglycemia, infection, bradycardia, exacerbation of hypertension, seizure, and sudden death (21).

PBN alleviates oxidative damage from ischemia/reperfusion injury by efficiently trapping ROS. ROS protect biologically important molecules from oxidative damage. While O2 free radicals and oxidative events have been implicated in DCS, there is no definitive proof that they are a main component of DCS. Our results are the first to show that a nitrone-based free radical scavenger has no effect on the incidence of DCS. Our doses were higher than those in the literature investigating ischemia/reperfusion and stroke (11). PBN’s ineffectiveness suggests that the formation of free radicals may not be important in DCS pathology.

Although TSC has shown promise in the treatment of hemorrhagic shock, our results indicate that it is not beneficial in the treatment of DCS. Treatment with 100% O2 is a widely used option for DCS treatment outside of recompression, thought to be due to enhancement of N2 off-gassing and the increase in the capillary partial pressure of O2 (45). Experience with 100% O2 breathing at 1 ATA is limited and anecdotal since no clinical trials have been performed. However, it is thought that breathing 100% O2 may relieve the symptoms of DCS and decrease the number of decompression treatments needed (45). TSC reputedly increases O2 diffusivity, but is ineffective in the treatment of DCS.

Conclusion

The need for further research in DCS adjuvant therapy is obvious. Human trials are ethically problematic due to the low incidence of DCS, emphasizing the importance of continued animal research. The ineffectiveness of the therapeutic agents we tested and the marginal results with lidocaine post-dive are convincing evidence that the hunt for an appropriate drug strategy against DCS will not be easy. While the results of this study do not support the use of any of these compounds in severe DCS, they may be useful in milder forms of the disease. Future studies should consider investigating adjuvants given in combinations. Since DCS is multiple-organ pathology, it may require two or three drugs impacting on different pathological mechanisms to attenuate or prevent DCS. Another area of future research should be adjuvant therapy during recompression and high-pressure O2 breathing. While the general incidence of DCS among Navy and sport divers is low, its impact can be severe and long lasting. An efficacious treatment or intervention could significantly impact military, commercial, and recreational divers, ameliorating the occurrence and sequelae of this disease.

ACKNOWLEDGMENTS

The authors thank Dr. John Gainer for kindly supplying the TSC. We also wish to thank Mr. William Porter, Mr. Donald Valentine, Mr. Daniel Brown, Mr. Melvin Routh, Mr. Darren Fryer, and Mr. Wayne Kollers for their excellent technical assistance. Thanks are also due to the staff of the Laboratory Animal Medicine and Science Department and Technical Services Department at NMRC. We are also grateful to Ms. Diana Temple for her help in preparation of the manuscript. Special thanks to Bob Burge and Lanju Zhang, MS, for statistical analysis and helpful comments to the manuscript.

This work was supported by Office of Naval Research work units 62236H1412.1M20.A0071 and 65706N0096.1330.A0071, IACUC K005-00. The opinions and assertions contained herein are those of the authors and are not to be construed as official or reflecting the views of the Navy Department or the naval service at large.

REFERENCES


